MarketPulse

PBC

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Ipsen

Ipsen's IQIRVO Shows Strong Real-World Efficacy in Primary Biliary Cholangitis

Ipsen presented clinical data on IQIRVO demonstrating 59% ALP normalization and significant fatigue improvements in primary biliary cholangitis patients.
IPSEYclinical trialPPAR agonist
GlobeNewswire Inc.GlobeNewswire Inc.··Ipsen

Ipsen's IQIRVO Shows Strong Real-World Efficacy in PBC Treatment Beyond Trials

Ipsen's IQIRVO shows 67% fatigue improvement vs. 31% placebo in Phase III, with real-world data confirming 59% ALP normalization and favorable tolerability in routine clinical practice.
IPSEYclinical trial resultsPPAR agonist